Caris Life Sciences to Present 32 Precision Oncology Studies at ASCO 2026

Caris Life Sciences will present 32 studies at the 2026 Annual Meeting of the American Society of Clinical Oncology, announced in a press release. The meeting will take place from May 29 to June 2, 2026, in Chicago.

The presentations include one rapid oral session and multiple posters covering 10 tumor types and pan-cancer analyses. The studies focus on multi-omic biomarker research and real-world data applications in precision oncology. Key research areas include immuno-oncology, tumor microenvironment characterization, and prediction of treatment response and resistance.

Among the highlights are two Caris-led studies. One investigates how genetic ancestry affects ultraviolet-related mutational signatures in melanoma and their link to immunotherapy response. Another examines ESR1 amplification in breast cancer as a genomic subtype associated with reduced survival and lower benefit from CDK4/6 inhibitor therapies.

The work involves collaborations with more than 60 institutions, including Dana-Farber Cancer Institute, Mayo Clinic, Memorial Sloan Kettering Cancer Center, and the National Cancer Institute. Abstracts and posters will be available at the Caris booth and on the company’s website following the event.